Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for IGM Biosciences, Inc. (IGMS : NSDQ)

• Company Description    IGM Biosciences Inc. is a biotechnology company. It engages in the research and development of engineered Immunoglobulin M antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM, which are in clinical stage. IGM Biosciences Inc. is based in Mountain View, California. Number of Employees: 258

• Price / Volume Information    Yesterday's Closing Price: $12.84 Daily Weekly Monthly 20 Day Moving Average: 206,845 shares Shares Outstanding: 43.08 (millions) Market Capitalization: $553.18 (millions) Beta: -0.23 52 Week High: $28.20 52 Week Low: $9.74 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.07% -1.80% 12 Week -32.78% -37.60% Year To Date -24.51% -31.34%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 325 EAST MIDDLEFIELD ROAD - MOUNTAIN VIEW,CA 94043 USA ph: 650-965-7873 fax: - None http://igmbio.com

• General Corporate Information    Officers Fred Schwarzer - Chief Executive Officer; President Michael Loberg - Chair of the Board of Directors Misbah Tahir - Chief Financial Officer Steven Weber - Senior Vice President; Corporate Controller Michael Lee - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 449585108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/14/23 Share - Related Items Shares Outstanding: 43.08 Most Recent Split Date: (:1) Beta: -0.23 Market Capitalization: $553.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.46 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.97 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 25.39% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.31 Price/Cash Flow: - Price / Sales: 347.69 EPS Growth vs. Year Ago Period: 13.07% vs. Previous Quarter: -11.76% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 40.32% ROE 03/31/23 - -74.30 12/31/22 - -73.99 09/30/22 - -76.03 ROA 03/31/23 - -43.54 12/31/22 - -46.69 09/30/22 - -52.21 Current Ratio 03/31/23 - 8.82 12/31/22 - 9.81 09/30/22 - 10.79 Quick Ratio 03/31/23 - 8.82 12/31/22 - 9.81 09/30/22 - 10.79 Operating Margin 03/31/23 - -14,363.10 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - -14,363.10 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - -14,357.64 12/31/22 - -20,683.07 09/30/22 - -31,444.48 Book Value 03/31/23 - 5.56 12/31/22 - 6.67 09/30/22 - 7.67 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©